Your browser doesn't support javascript.
loading
A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech.
Josephs, Keith A; Duffy, Joseph R; Clark, Heather M; Utianski, Rene L; Strand, Edythe A; Machulda, Mary M; Botha, Hugo; Martin, Peter R; Pham, Nha Trang Thu; Stierwalt, Julie; Ali, Farwa; Buciuc, Marina; Baker, Matthew; Fernandez De Castro, Cristhoper H; Spychalla, Anthony J; Schwarz, Christopher G; Reid, Robert I; Senjem, Matthew L; Jack, Clifford R; Lowe, Val J; Bigio, Eileen H; Reichard, Ross R; Polley, Eric J; Ertekin-Taner, Nilufer; Rademakers, Rosa; DeTure, Michael A; Ross, Owen A; Dickson, Dennis W; Whitwell, Jennifer L.
Afiliação
  • Josephs KA; Department of Neurology, Mayo Clinic, Rochester, MN, USA. josephs.keith@mayo.edu.
  • Duffy JR; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Clark HM; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Utianski RL; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Strand EA; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Machulda MM; Speech & Hearing Sciences, University of Washington, Seattle, WA, USA.
  • Botha H; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
  • Martin PR; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Pham NTT; Department of Quantitative Health Sciences (Biostatistics), Mayo Clinic, Rochester, MN, USA.
  • Stierwalt J; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Ali F; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Buciuc M; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Baker M; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Fernandez De Castro CH; Department of Neuroscience, Jacksonville, FL, USA.
  • Spychalla AJ; Department of Neuroscience, Jacksonville, FL, USA.
  • Schwarz CG; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Reid RI; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Senjem ML; Department of Information Technology, Rochester, MN, USA.
  • Jack CR; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Lowe VJ; Department of Information Technology, Rochester, MN, USA.
  • Bigio EH; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Reichard RR; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Polley EJ; Department of Pathology, Northwestern University School of Medicine, Chicago, IL, USA.
  • Ertekin-Taner N; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Rademakers R; Department of Quantitative Health Sciences (Biostatistics), Mayo Clinic, Rochester, MN, USA.
  • DeTure MA; Department of Neuroscience, Jacksonville, FL, USA.
  • Ross OA; Department of Neuroscience, Jacksonville, FL, USA.
  • Dickson DW; VIB-UA Center for Molecular Neurology, VIB, University of Antwerp, Antwerp, Belgium.
  • Whitwell JL; Department of Neuroscience, Jacksonville, FL, USA.
Nat Commun ; 12(1): 3452, 2021 06 08.
Article em En | MEDLINE | ID: mdl-34103532
Progressive apraxia of speech is a neurodegenerative syndrome affecting spoken communication. Molecular pathology, biochemistry, genetics, and longitudinal imaging were investigated in 32 autopsy-confirmed patients with progressive apraxia of speech who were followed over 10 years. Corticobasal degeneration and progressive supranuclear palsy (4R-tauopathies) were the most common underlying pathologies. Perceptually distinct speech characteristics, combined with age-at-onset, predicted specific 4R-tauopathy; phonetic subtype and younger age predicted corticobasal degeneration, and prosodic subtype and older age predicted progressive supranuclear palsy. Phonetic and prosodic subtypes showed differing relationships within the cortico-striato-pallido-nigro-luysial network. Biochemical analysis revealed no distinct differences in aggregated 4R-tau while tau H1 haplotype frequency (69%) was lower compared to 1000+ autopsy-confirmed 4R-tauopathies. Corticobasal degeneration patients had faster rates of decline, greater cortical degeneration, and shorter illness duration than progressive supranuclear palsy. These findings help define the pathobiology of progressive apraxia of speech and may have consequences for development of 4R-tau targeting treatment.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apraxias / Fala / Progressão da Doença / Neuroimagem Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apraxias / Fala / Progressão da Doença / Neuroimagem Idioma: En Ano de publicação: 2021 Tipo de documento: Article